Improvement of survival in patients with primary cutaneous diffuse large B-cell lymphoma, leg type, in France

JAMA Dermatology

Volumn 150, Issue 5, 2014, Pages 535-541

  Grange, Florent ^a   Joly, Pascal ^b   Barbe, Coralie ^a   Bagot, Martine ^c   Dalle, Stéphane ^d   Ingen Housz Oro, Saskia ^e   Maubec, Eve ^f   D'Incan, Michel ^g   Ram Wolff, Caroline ^c   Dalac, Sophie ^h   Templier, Isabelle ⁱ   Esteve, Eric ^j   Quereux, Gaëlle ^k   Machet, Laurent ^l   Leduc, Marion ^m   Dereure, Olivier ⁿ   Laroche, Liliane ^o   Saiag, Philippe ^p   Vergier, Béatrice ^q   Beylot Barry, Marie ^q  

^a SERVICE DE DERMATOLOGIE   (France)

^b HÔPITAL CHARLES NICOLLE   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d HÔTEL DIEU   (France)

^e HENRI MONDOR HOSPITAL   (France)

^f BICHAT HOSPITAL   (France)

^g HÔTEL DIEU   (France)

^h HÔPITAL DU BOCAGE   (France)

ⁱ HÔPITAL MICHALLON   (France)

^j Hôpital Porte Madeleine   (France)

^k HÔTEL DIEU   (France)

^l SERVICE DE DERMATOLOGIE   (France)

^m HÔPITAL MAISON BLANCHE   (France)

ⁿ HÔPITAL SAINT ELOI   (France)

^o AVICENNE HOSPITAL   (France)

^p HÔPITAL AMBROISE PARÉ   (France)

^q HAUT LÉVÊQUE HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CORTICOSTEROID; LACTATE DEHYDROGENASE; RITUXIMAB;

AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SPECIFIC SURVIVAL; CANCER STAGING; DOSE RESPONSE; FEMALE; FRANCE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKIN LYMPHOMA; SURVIVAL RATE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAUSE OF DEATH; COHORT STUDIES; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOWER EXTREMITY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEX FACTORS; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 84901020794     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2013.7452     Document Type: Article

References (26)

1. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768-3785.
2. Grange F, Bekkenk MW, Wechsler J, et al. Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study. J Clin Oncol. 2001;19(16):3602-3610.
3. Grange F, Petrella T, Beylot-Barry M, et al. Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas. Blood. 2004;103(10):3662-3668.
4. Grange F, Beylot-Barry M, Courville P, et al. Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. Arch Dermatol. 2007;143(9):1144-1150.
5. Hoefnagel JJ, Dijkman R, Basso K, et al. Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood. 2005;105(9):3671-3678.
6. Vermeer MH, Geelen FA, Van Haselen CW, et al; Dutch Cutaneous LymphomaWorking Group. Primary cutaneous large B-cell lymphomas of the legs: a distinct type of cutaneous B-cell lymphoma with an intermediate prognosis. Arch Dermatol. 1996;132(11):1304-1308.
7. Senff NJ, Hoefnagel JJ, Jansen PM, et al. Reclassification of 300 primary cutaneous B-cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. J Clin Oncol. 2007;25(12):1581-1587.
8. Kodama K, Massone C, Chott A, Metze D, Kerl H, Cerroni L. Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients. Blood. 2005;106(7):2491-2497.
9. Zinzani PL, Quaglino P, Pimpinelli N, et al. Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas. J Clin Oncol. 2006;24(9):1376-1382.
10. Bessell EM, Humber CE, O'Connor S, et al. Primary cutaneous B-cell lymphoma in Nottinghamshire U. K.: prognosis of subtypes defined in the WHO-EORTC classification. Br J Dermatol. 2012;167(5):1118-1123.
11. Hallermann C, Niermann C, Fischer R-J, Schulze H-J. Survival data for 299 patients with primary cutaneous lymphomas: a monocentre study. Acta Derm Venereol. 2011;91(5):521-525.
12. Senff NJ, Noordijk EM, Kim YH, et al; European Organization for Research and Treatment of Cancer; International Society for Cutaneous Lymphoma. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood. 2008;112(5):1600-1609.
13. Sokol L, Naghashpour M, Glass LF. Primary cutaneous B-cell lymphomas: recent advances in diagnosis and management. Cancer Control. 2012;19(3):236-244.
14. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242.
15. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010;116(12):2040-2045.
16. Grange F, Maubec E, Bagot M, et al. Treatment of cutaneous B-cell lymphoma, leg type, with age-Adapted combinations of chemotherapies and rituximab. Arch Dermatol. 2009;145(3):329-330.
17. Kim YH, Willemze R, Pimpinelli N, et al; ISCL and the EORTC. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(2):479-484.
18. Thieblemont C, Coiffier B. Lymphoma in older patients. J Clin Oncol. 2007;25(14):1916-1923.
19. Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-Associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood. 2003;101(11):4279-4284.
20. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23(18):4117-4126.
21. Grange F, D'Incan M, Ortonne N, et al; pour le Groupe français d'étude des lymphomes cutanés. Management of cutaneous B-cell lymphoma: recommendations of the French cutaneous lymphoma study group [in French]. Ann Dermatol Venereol. 2010;137(8-9):523-531.
22. Italiano A, Jardin F, Peyrade F, Saudes L, Tilly H, Thyss A. Adapted CHOP plus rituximab in non-Hodgkin's lymphoma in patients over 80 years old. Haematologica. 2005;90(9):1281-1283.
23. Guyot A, Ortonne N, Valeyrie-Allanore L, Bagot M. Combined treatment with rituximab and anthracycline-containing chemotherapy for primary cutaneous large B-cell lymphomas, leg type, in elderly patients. Arch Dermatol. 2010;146(1):89-91.
24. Coiffier B. When can R-CHOP not be used in an elderly patient? Oncology (Williston Park). 2013;27(2):146-148.
25. Aapro MS, Cameron DA, Pettengell R, et al; European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) GuidelinesWorking Party. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006;42(15):2433-2453.
26. Aapro MS, Bohlius J, Cameron DA, et al; European Organisation for Research and Treatment of Cancer. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8-32.